Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECR-DAMI: Semaglutide in early cardiac remodeling after acute myocardial infarction in patients with type 2 diabetes
ChiCTR2500101327Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in myocardial infarction (MI), type 2 diabetes mellitus (T2DM) and cardiac remodeling (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Assessment of ventricular remodeling by UCG. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)cardiac remodeling
Beyond the preview
Go deeper on ChiCTR2500101327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101327.